{'fraction_non_alphanumeric': 0.034482758620689655, 'fraction_numerical': 0.018148820326678767, 'mean_word_length': 5.3028571428571425, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract IA16: The interplay between RAS/MAPK signaling and tumor immunology

The role of MAPK in regulating the expression of pathways important for immune recognition of tumors such as modulation of the antigen presenting machinery and MHC Class I expression is now well studied preclinically. The clinical experience of the combination of MAPK inhibition with checkpoint inhibition (anti-PD-L1/PD-1) in cancer, however, has been less understood. Here, we will review the clinical data for checkpoint inhibitors and correlation with outcomes in the context of KRAS mutations in lung cancer and melanoma. In addition, the clinical activity of combinations of checkpoint inhibitors with MAPK inhibitors will be reviewed for both inflamed cancers such as melanoma and noninflamed cancers such as colorectal cancer. Citation Format: Priti Hegde. The interplay between RAS/MAPK signaling and tumor immunology [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr IA16.